Menu
![]() Despite the original CRM design being proposed in 1990, the methodology is still not widely implemented within oncology Phase I trials. CRM designsare a class of adaptive design that select the dose to be given to the next recruited patient based on accumulating toxicity data from patients already recruited into the trial, often using Bayesian methodology. ![]() ![]() This paper presents the R package bcrm for conducting and assessing Bayesian continual reassessment method (CRM) designs in Phase I dose-escalation trials.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |